Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Haemocomplettan P in congenital fibrinogen deficiency
2006-006023-39Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fibrinogen human in fibrinogen deficiency and congenital afibrinogenemia, sponsored by CSL Limited. Primary endpoints: Maximum clot firmness (MCF) 1 hour post-dose vs baseline and Safety of Haemocomplettan P. Started Jun 2007; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
fibrinogen deficiencycongenital afibrinogenemia
Beyond the preview
Go deeper on 2006-006023-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006023-39.